Day One to file NDA for pediatric brain cancer drug by summer

Kyle LaHucik

Senior Reporter

Day One Biopharmaceuticals will ask regulators to approve its pediatric brain cancer drug tovorafenib before the second half of 2023, the biotech said Sunday. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Day One to file NDA for pediatric brain cancer drug by summer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

CMS explains what went into its first round of drug price negotiations

Day One to file NDA for pe­di­atric brain can­cer drug by sum­mer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Day One to file NDA for pediatric brain cancer drug by summer

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

CMS explains what went into its first round of drug price negotiations